Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced the appointment of Dr. Christian Schetter, Ph.D. as Chief Scientific Officer (CSO) of Rentschler Biopharma SE, where he will be responsible for process technology and innovation, effective 15 September 2021. In this position, he will be working with a team of experienced scientists to ensure Rentschler Biopharma's continued technological and scientific leadership in process development and further develop strategic innovation and partnerships.
With more than 30 years of experience in biotechnological science and in the life sciences industry as well as in various executive and supervisory board functions, Dr. Schetter has a proven track record across the entire biopharmaceutical value chain.
Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma, said: “I am delighted that Dr. Schetter has joined Rentschler Biopharma as our new Chief Scientific Officer. Our goal at Rentschler is to create lasting benefits. By continuously advancing our knowledge in the development and production of essential biopharmaceuticals, we are contributing to improving the health and quality of life of seriously ill people. A pioneering spirit, innovation and the power of science have always played a pivotal role for us. Dr. Schetter has an impressive track record in both, the scientific and strategic development of companies, and therefore ideally complements our management team.”
“With Dr. Christian Schetter, we are not only gaining an excellent scientist, but also a very experienced leader and strategic innovator. It is with great pleasure that I welcome him as our new CSO,” commented Dr. Frank Mathias, CEO of Rentschler Biopharma. “Dr. Schetter, our CFO Alexander Dettmer and I have already successfully implemented joint projects across companies in the past. We have great trust and appreciation for one another and are looking forward to continuing this long-standing relationship. Together with a strong leadership team, we will implement our ‘Strategy 2025’ – and beyond – and continue to position our company at the forefront of innovation and technology.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!